ATE370738T1 - Verwendung von eplerenon zur behandlung von restenose - Google Patents

Verwendung von eplerenon zur behandlung von restenose

Info

Publication number
ATE370738T1
ATE370738T1 AT00977121T AT00977121T ATE370738T1 AT E370738 T1 ATE370738 T1 AT E370738T1 AT 00977121 T AT00977121 T AT 00977121T AT 00977121 T AT00977121 T AT 00977121T AT E370738 T1 ATE370738 T1 AT E370738T1
Authority
AT
Austria
Prior art keywords
eplerenone
restenoses
treat
pathogenic change
resulting
Prior art date
Application number
AT00977121T
Other languages
English (en)
Inventor
John Delyani
Kenton Fedde
John Funder
Michael Ward
Peter Kanellakis
Alex Bobik
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Application granted granted Critical
Publication of ATE370738T1 publication Critical patent/ATE370738T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
AT00977121T 1999-11-09 2000-11-08 Verwendung von eplerenon zur behandlung von restenose ATE370738T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16439099P 1999-11-09 1999-11-09

Publications (1)

Publication Number Publication Date
ATE370738T1 true ATE370738T1 (de) 2007-09-15

Family

ID=22594274

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00977121T ATE370738T1 (de) 1999-11-09 2000-11-08 Verwendung von eplerenon zur behandlung von restenose

Country Status (9)

Country Link
US (1) US20040067916A1 (de)
EP (1) EP1227804B1 (de)
JP (1) JP2003513913A (de)
AT (1) ATE370738T1 (de)
AU (2) AU1480301A (de)
CA (1) CA2390561A1 (de)
DE (1) DE60036122T2 (de)
ES (1) ES2288487T3 (de)
WO (1) WO2001034132A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009683A2 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AU2003227454B2 (en) * 2002-04-22 2009-07-30 Research Foundation Itsuu Laboratory Medicament for therapeutic treatment of vascular disease
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
DE60330888D1 (de) * 2002-11-05 2010-02-25 Bayer Schering Pharma Ag Verwendung von drospirenon zur behandlung von hypertension
US20050014732A1 (en) * 2003-03-14 2005-01-20 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-diabetic agent
US20050232957A1 (en) * 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin
WO2006092430A1 (de) 2005-03-03 2006-09-08 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
JP5953035B2 (ja) * 2011-11-28 2016-07-13 学校法人慶應義塾 病理診断支援装置、病理診断支援方法、及び病理診断支援プログラム
US20190328753A1 (en) * 2015-03-03 2019-10-31 Richard W. Yee Compositions and methods for treating ocular diseases
WO2016141182A1 (en) * 2015-03-03 2016-09-09 Yee Richard W Compositions and methods for treating ocular diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
WO1996040255A2 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
WO2000010552A2 (en) * 1998-08-24 2000-03-02 Global Vascular Concepts, Inc. Use of anti-angiogenic agents for inhibiting vessel wall injury

Also Published As

Publication number Publication date
JP2003513913A (ja) 2003-04-15
DE60036122T2 (de) 2008-05-15
AU1480301A (en) 2001-06-06
EP1227804B1 (de) 2007-08-22
EP1227804A2 (de) 2002-08-07
AU2005229683A1 (en) 2005-12-01
DE60036122D1 (de) 2007-10-04
ES2288487T3 (es) 2008-01-16
WO2001034132A3 (en) 2002-01-24
US20040067916A1 (en) 2004-04-08
WO2001034132A2 (en) 2001-05-17
CA2390561A1 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
ATE370738T1 (de) Verwendung von eplerenon zur behandlung von restenose
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
HUS1600020I1 (hu) Módosított VIII-as faktor
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
PT1187918E (pt) Antagonistas de tek
MY121136A (en) Novel heterocyclic sulfonamides.
ATE438404T1 (de) Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
DE60025639D1 (de) Substituierte diazepan
SI1608685T1 (sl) Antagonisti VEGF za zdravljenje diabetesa
DE69815788D1 (de) Verwendung von Des-Aspartate Angiotensin I zur Herstellung eines Arzneimittels zur Vorbeugung und Behandlung von Atherosclerose, Neointimabildung und Restenose
ATE517617T1 (de) Behandlung von parkinson erkrankung mit kape
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60023139D1 (de) Verwendung von il6r- il6 chimären für die behandlung von neurodegenerativen erkankungen
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
ATE338566T1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer- kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
ATE432359T1 (de) Modulation der s6-kinaseaktivität zur behandlung von adipositas
DE60007864D1 (de) Verwendung von antileukoprotease zur behandlung von endometriose
DE60210769D1 (de) Verwendung von bicyklischen verbindungen für die behandlung von alzheimer
ATE358488T1 (de) Behandlung von dyskinesie mit 2,3-benzodiazepinen
DE69808607D1 (de) Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties